Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125 -0.74% 16.875 16.50 17.25 17.00 16.75 17.00 206,781 15:34:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.4 -0.9 - 20

SkinBioTherapeutics PLC Change of Adviser

26/06/2020 7:00am

UK Regulatory (RNS & others)


Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart


From Apr 2020 to Oct 2020

Click Here for more Skinbiotherapeutics Charts.

TIDMSBTX

RNS Number : 1484R

SkinBioTherapeutics PLC

26 June 2020

26 June 2020

SkinBioTherapeutics plc

Change of Adviser

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces that Cenkos Securities plc has been appointed with immediate effect as the Company's Nominated Adviser and Sole Broker.

 
 SkinBioTherapeutics plc                            Tel: +44 (0) 161 
                                                     468 2760 
 Stuart Ashman, CEO 
 Doug Quinn, CFO 
 
 Cenkos Securities plc (Nominated Adviser &         Tel: +44 (0)20 7397 
  Broker)                                            8900 
 Giles Balleny, Max Gould (Corporate Finance) 
 Michael Johnson (Sales) 
 Instinctif Partners                                Tel: +44 (0) 20 7457 
                                                     2020 
 Melanie Toyne-Sewell / Phillip Marriage / Nathan    SkinBio@instinctif.com 
  Billis 
 
 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:

www.skinbiotherapeutics.com   . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPBCGDLGXDDGGU

(END) Dow Jones Newswires

June 26, 2020 02:00 ET (06:00 GMT)

1 Year Skinbiotherapeutics Chart

1 Year Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart
ADVFN Advertorial
Your Recent History
LSE
SBTX
Skinbiothe..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201021 18:31:10